Biotechnology Businesses for Sale and Investment in Thiruvananthapuram

Client base: Served a wide range of B2B and B2C clients, including corporates, institutions, and individual customers during the COVID-19 period through sanitizer supply. - Currently working with multiple researchers, organizations, and academic institutions for product formulation, outsourcing works, and collaborative projects. - Revenue model: Product sales – Revenue from biotech-based products (e. g. , sanitizers, organic formulations). Services – Income from outsourcing works, product formulation contracts, and collaborative R&D. Training & projects – Fees from student training programs and academic project guidance in biotechnology and life sciences. We get about INR 3-6 lakh of monthly revenue from the services mentioned above. - Promoter experience: The business is led by promoters with strong academic and professional backgrounds in biotechnology research, product development, and laboratory management, with proven expertise in collaborations and student mentorship. - Business relationships: Established strong collaborations with researchers, universities, and organizations for outsourcing projects, technology development, and training initiatives. - Business has a certificate of incorporation and GST certificate. - Awards & Recognition: Mockingjay Award. IVAEX Women’s Day Award. Recognized for contributions during COVID-19 through large-scale sanitizer supply. Appreciated by academic institutions for providing consistent training and project opportunities to students.

Offer genetic testing and wellness management services, currently reaching 1,069 customers. - Product development completed, revenue generation started, franchisee appointments, academic programs, and community projects in progress. - Company that provides clients with a vision & understanding of their unique genetic profile and its implication for better wellness. - The field of health genomics has matured in the past two decades and is beginning to deliver genomic-based interventions for health and health care. Every human being will have huge amounts of genetic variation that create the unique individuality seen in a person. - Generate revenue by charging fees for tests to conduct. We charge around INR 20,000-60,000 for consumer genomic tests. - We have 32 employees (lab team, technical team, genetic team, customer support team, and marketing team). - The promoter has 13 years of experience in this industry.

Company and product: Enbiosis has developed an advanced artificial intelligence algorithm that analyzes the human gut microbiome and recommends personalized food and supplements to individuals to improve their gut health and address chronic disorders such as gastrointestinal disorders, skin-related disorders, and weight loss issues. - How it works: Patients/customers send their stool samples to any NGS laboratory in their region. Enbiosis takes the raw bacterial DNA data to the local server (to avoid data protection risks) and creates a personalized report, which is sent to patients and, if required, their practitioners within minutes. - Business model: Enbiosis's microbiome test can be sold through practitioners and/or directly to customers, depending on market dynamics. Practitioners can prescribe the test to patients to generate a personalized diet plan, or patients can follow their personalized nutrition guide through the app to improve general well-being and solve their problems. - Main differentiation: Enbiosis is the only clinically proven precision diet technology that claims to address the main cause of chronic disorders. It has conducted three clinical trials and published the results in peer-reviewed journals. Enbiosis's claims are backed by scientific evidence. - The main reason why investors should consider Enbiosis: In recent years, the number of people seeking to address their health problems through alternative methods instead of pharmaceuticals has been increasing. The challenge in alternative medicine is the lack of scientific data. Enbiosis serves as a bridge between alternative medicine and conventional medicine, and there is significant market potential for Enbiosis. For example, Enbiosis has proven the effectiveness of its technology in patients with IBS, who make up about 10% of the population. Offering individuals the opportunity to solve their chronic problems simply by changing their diet within a specific period is something they are interested in and willing to try. - Additionally, investors/distributors can offer a routine follow-up program to check gut health and prevent any kind of diseases, opening the door to long-term recurring revenue. - We have a trade registration certificate to operate.

Company and product: Enbiosis has developed an advanced artificial intelligence algorithm that analyzes the human gut microbiome and recommends personalized food and supplements to individuals to improve their gut health and address chronic disorders such as gastrointestinal disorders, skin-related disorders, and weight loss issues. - How it works: Patients/customers send their stool samples to any NGS laboratory in their region. Enbiosis takes the raw bacterial DNA data to the local server (to avoid data protection risks) and creates a personalized report, which is sent to patients and, if required, their practitioners within minutes. - Business model: Enbiosis's microbiome test can be sold through practitioners and/or directly to customers, depending on market dynamics. Practitioners can prescribe the test to patients to generate a personalized diet plan, or patients can follow their personalized nutrition guide through the app to improve general well-being and solve their problems. - Main differentiation: Enbiosis is the only clinically proven precision diet technology that claims to address the main cause of chronic disorders. It has conducted three clinical trials and published the results in peer-reviewed journals. Enbiosis's claims are backed by scientific evidence. - The main reason why investors should consider Enbiosis: In recent years, the number of people seeking to address their health problems through alternative methods instead of pharmaceuticals has been increasing. The challenge in alternative medicine is the lack of scientific data. Enbiosis serves as a bridge between alternative medicine and conventional medicine, and there is significant market potential for Enbiosis. For example, Enbiosis has proven the effectiveness of its technology in patients with IBS, who make up about 10% of the population. Offering individuals the opportunity to solve their chronic problems simply by changing their diet within a specific period is something they are interested in and willing to try. - Additionally, investors/distributors can offer a routine follow-up program to check gut health and prevent any kind of diseases, opening the door to long-term recurring revenue. - We have a trade registration certificate to operate.